Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Bruker (BRKRP) Gains from Sales and Divestitures (2016 - 2025)

Bruker's Gains from Sales and Divestitures history spans 14 years, with the latest figure at $299973.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 10.5% year-over-year to $299973.0; the TTM value through Dec 2025 reached $299973.0, up 10.5%, while the annual FY2025 figure was $299973.0, 10.5% up from the prior year.
  • Gains from Sales and Divestitures reached $299973.0 in Q4 2025 per BRKRP's latest filing, up from $271477.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $299973.0 in Q4 2025 to a low of $266395.0 in Q4 2023.
  • Average Gains from Sales and Divestitures over 4 years is $278804.6, with a median of $275082.0 recorded in 2022.
  • Peak YoY movement for Gains from Sales and Divestitures: dropped 5.23% in 2023, then increased 10.5% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $281096.0 in 2022, then fell by 5.23% to $266395.0 in 2023, then grew by 1.91% to $271477.0 in 2024, then increased by 10.5% to $299973.0 in 2025.
  • Per Business Quant, the three most recent readings for BRKRP's Gains from Sales and Divestitures are $299973.0 (Q4 2025), $271477.0 (Q4 2024), and $266395.0 (Q4 2023).